by 陸蓉
神蓉世~ 生技大小事 -- Hosting provided by <a href="https://www.soundon.fm/" target="_blank">SoundOn</a>
Language
🇨🇳
Publishing Since
2/5/2023
Email Addresses
1 available
Phone Numbers
0 available
March 3, 2025
EP21|3,000 萬美元買一張血癌藥證,漢達生技這筆交易值不值? 🔹這款藥憑什麼值 3,000 萬? 🔹3 年市場專賣期 vs. 罕見藥 7 年專賣期,這場豪賭能成功嗎? 🔹可搭配制酸劑使用,搶佔 20% 特殊市場! 🔹原廠 年銷 14 億美元,漢達能從中分一杯羹? 🔹原廠為何自己不買,反而拱手讓人? ⚡️相關連結 EP02|多發性硬化症、新劑型新藥、漢達生技 <a href="https://youtu.be/pIDUkHDzVfk">https://youtu.be/pIDUkHDzVfk</a> EP12|昱展新藥、戒毒癮長效針劑 <a href="https://youtu.be/E9SjXMEDCgQ">https://youtu.be/E9SjXMEDCgQ</a> 💡專有名詞: ▪️美國公司Nanocopoeia, LLC ▪️血癌藥Phyrago® (成分 Dasatinib) ▪️Philadelphia 染色體突變的血癌 📢 留言告訴我們,你覺得這筆交易值不值得? -- Hosting provided by <a href="https://www.soundon.fm/">SoundOn</a>
February 23, 2025
一場晶片產業的角力,美國政府開出三個方案,這是合作?還是逼台積電拱手讓人? 這集重點: 🔹Intel 曾經的霸主地位,為何被台積電反超? 🔹美國政府如何施壓台積電,逼它與 Intel 合作? 🔹美積電計畫、100% 關稅,對台積電是機會還是風險? -- Hosting provided by <a href="https://www.soundon.fm/">SoundOn</a>
February 16, 2025
康霈生技(6919)在2022/12興櫃,股價已翻 8.5 倍, 2025/2/10已超越保瑞,成為台灣生技新科股王! 🚀 但這背後是資本市場的炒作?還是 康霈生技 真的有顛覆市場的潛力? 🔹 一藥多適應症:局部減脂針、橘皮、竇根氏症 (罕見脂肪瘤) 🔹 競爭對手分析:冷凍溶脂、超音波減脂 🔹 兩個原因推升股價 👉 這集不只聊生技股,還解析醫美新藥市場,千萬別錯過! 🎧 FB:www.facebook.com/rong.rx.fb IG:www.instagram.com/rong.rx -- Hosting provided by <a href="https://www.soundon.fm/">SoundOn</a>
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.